Connor, Clark & Lunn Investment Management (CC&L)’s Rigel Pharmaceuticals RIGL Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$2.25M Sell
83,129
-24,840
-23% -$835K 0.01% 927
2025
Q4
$4.62M Sell
107,969
-120,426
-53% -$4.54M 0.01% 666
2025
Q3
$6.47M Buy
228,395
+80,212
+54% +$2.4M 0.02% 512
2025
Q2
$2.78M Sell
148,183
-9,741
-6% -$185K 0.01% 761
2025
Q1
$2.84M Buy
157,924
+18,796
+14% +$381K 0.01% 641
2024
Q4
$2.34M Buy
139,128
+41,122
+42% +$789K 0.01% 679
2024
Q3
$1.59M Buy
98,006
+22,443
+30% +$264K 0.01% 729
2024
Q2
$621K Buy
75,563
+2,307
+3% +$24.1K ﹤0.01% 993
2024
Q1
$1.08M Buy
73,256
+14,355
+24% +$193K ﹤0.01% 858
2023
Q4
$854K Sell
58,901
-262
-0.4% -$2.68K ﹤0.01% 903
2023
Q3
$639K Sell
59,163
-896
-1% -$10.8K ﹤0.01% 958
2023
Q2
$775K Buy
60,059
+1,720
+3% +$23.3K ﹤0.01% 870
2023
Q1
$770K Buy
58,339
+1,060
+2% +$16.8K ﹤0.01% 782
2022
Q4
$859K Buy
+57,279
New +$525K ﹤0.01% 743
2017
Q4
Sell
-1,014
Closed -$26K 843
2017
Q3
$26K Sell
1,014
-11,778
-92% -$286K ﹤0.01% 797
2017
Q2
$349K Sell
12,792
-8,473
-40% -$232K ﹤0.01% 661
2017
Q1
$704K Sell
21,265
-1,849
-8% -$47.1K ﹤0.01% 560
2016
Q4
$550K Sell
23,114
-8,920
-28% -$255K ﹤0.01% 586
2016
Q3
$1.18M Sell
32,034
-10,920
-25% -$313K 0.01% 450
2016
Q2
$958K Hold
42,954
0.01% 472
2016
Q1
$893K Sell
42,954
-3,113
-7% -$76.8K 0.01% 475
2015
Q4
$1.4M Buy
46,067
+5,822
+14% +$177K 0.01% 392
2015
Q3
$994K Buy
40,245
+15,585
+63% +$465K 0.01% 402
2015
Q2
$792K Buy
24,660
+10,120
+70% +$387K 0.01% 367
2015
Q1
$519K Buy
14,540
+12,630
+661% +$346K ﹤0.01% 388
2014
Q4
$43K Buy
+1,910
New +$38.6K ﹤0.01% 568
2014
Q2
Sell
-2,162
Closed -$93K 617
2014
Q1
$93K Buy
+2,162
New +$77.1K ﹤0.01% 653

Other funds holding RIGL